HOME > Investors > Press Releases
2016-06-28
VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
2016-05-18
VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis (ALS)
2016-04-25
Iranian, Korean firms ink MOU on traditional medicine
2016-03-23
2016.03(IR letter) Business Updates
2016-01-25
ViroMed reports operating profit increased by 342% from previous year
1 2 3 4 5 6 7 8 9 10